Moderators: ORCA , Stef07 , slops , whatarush12
Search This Board: 
Created: 10/27/2008 02:19:39 PM - Followers: 619 - Board type: Free - Posts Today: 6



A Division of ViaDerma, Inc. , A Public Company.

Breakthrough Rapid Delivery of Nutrients and Medicines

ViaDerma, Inc. is a biotechnology licensing company committed to bringing new products quickly to the pharmaceutical industry through innovative research & development. ViaDerma licenses products in fields of medicine ranging from infectious diseases to stem-cell therapy.

About Our Products

Proprietary and Trade Secret Mechanism of Action

ViaDerma's proprietary transdermal delivery system allows for rapid mass transfer of the pharmaceutical active ingredient across the skin and into the body to provide immediate localized therapy.

The technology allows transfer of chemicals through the stratum corneum (outer layer of skin) with a diffusion constant which is 10,000 times higher than the diffusion constant which characterizes water movement through the stratum corneum.

This enables ViaDerma to pair almost any active ingredient with the technology and provide rapid transport of the medicine right to the site of action.

The first product is a broad spectrum tetracycline-based topical antibiotic is the only antibiotic in the world that kills bacteria both a physical and a chemical mechanism. All known antibiotics (other than ours) primarily use only a chemical mechanism of kill. The physical mechanism of kill is a key feature of what we call Rapid Active Ingredient Delivery System (RAIDS). One result of RAIDS is that tetracycline is carried in higher concentrations, more quickly, to and through the cell walls, where the tetracycline can become more effective than if conventional antibiotics were used. Conventional antibiotics require more time (usually prescribed for 5 to 7 days for best results), whereas our tetracycline-based products usually produce desirable results in 24 hours (or less) because of the RAIDS effect.

Skin Layer Organization

A second important result of RAIDS is that the topical antibiotic kills all harmful Gram positive and Gram negative bacteria that have been available for testing. We believe this is the world’s strongest broad-spectrum topical antibiotic available.

The potential commercial impact is immense. Drug developers believe it takes much longer for bacteria to develop drug resistance to a physical kill mechanism. This is because it is relatively easy for bacteria to change their response to a chemical threat, but it takes numerous generations for bacteria to grow a new kind of cell wall structure to respond to a physical threat.

Our novel approach to overcome drug resistance of antibiotics is designed to sustain the effectiveness of antibiotics and other topical drugs for many years. This gives new topical drug products a longer useful lifetime and therefore more commercial value. This technology, when licensed to larger pharmaceutical companies, may provide stronger incentive for the discovery and development of new antimicrobial drugs. In recent years, the dearth of new antibiotics has been largely due to the uncertain new-drug commercial lifetime which is diminished when bacteria develop immunity to that drug.

In addition the technology can be licensed to other companies to convert existing oral drugs to transdermal medications extending the profitably of the existing drug.


Available at ....

ViaDerma Licensing FaceBook page at...


Vitastem treats Acne, Burns, Eczema, Infections, Psoriasis and Wounds

We are developing products in the following fields of use;

Topical antibiotics

Treats all types of bacteria including MRSA, VRE and other flesh eating bacteria. Fights drug resistant bacteria. $6B/year global market.

  • Estimated Global prevalence rate of all types of bacterial infection including pets: 2 Billion.
    Estimated Global prevalence rate of MRSA: 140 million.
Topical toenail antifungal

Onychomycosis, a fungal infection of the toenails, is a major health problem. It is estimated that there are in excess of 40 million sufferers with this condition in the USA. It is a problem throughout the world. A recent European study showed that the prevalence of Onychomycosis may be as high as 26.9%. Fungal resistance can occur when the oral antifungal agents are used on a long-term basis. Topically applied antifungal drugs may work somewhat better adjunctive to surgical removal or chemical dissolution of the nail plate. Yet, this often ineffective and traumatic procedure leaves the subject without a nail for months at risk for re-infection. Given the limitations of current treatment options in this $3B market, there is a great need for a simple, nontoxic and effective alternative treatment. Estimated Global prevalence rate: 140 million.

Anti-viral formula

Treats symptoms of Influenza which is a$4B/ year global market: Common

  • Estimated Global prevalence rate of Influenza: 355-1065 million.
    Estimated Global prevalence rate of “Bird Flu”: Very rare, about 500 cases.
    Estimated Global prevalence rate of “Swine Flu”: 1420 million were infected in 2009
Wound care

Diabetic foot wounds.

  • Diabetic foot Ulcers; $1.5B/year global market. 12 million people per year

We are currently in discussions with companies in Australia & New Zealand, India, China, and West Africa.


Contact Details

ViaDerma's global headquarters is located at

4640 Admiralty Way, Ste 500

Marina Del Rey, CA 90292

Phone: 310-496-5744





CBD Product launch!!!  

Initial order of 1,000 units sold into Canada have SOLD OUT!


Per 3/8/18 PR: ViaDerma’s technology is currently being used in Elixr Cannabis products; Topical Balm, Topical Serum and Topical Spray. Sales have begun in Canada.

Per 12/7/17 PR:  The Company has signed an MOU and will start production of its Patent Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent #62466209, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent # 62433964 for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinary uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. 

Per 1/23/18 PR:  The Company has also a licensing and distribution agreement in place with its Canadian partners to produce a CBD Topical Serum, which has a 92% absorption rate powered by ViaDerma's Patent Pending Dual Carrier Technology. The CBD and Terpene profile (enriched with specific essential oils and vitamins C, and D) is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. The serum has anti-inflammatory, anti-bacterial, and chronic pain relief properties that are absorbed by the skin and provide overall healing benefits. Sales are expected to begin in the first quarter of 2018 and are projected to generate approximately $2 million annual revenues.

The Patented Pending CBD or Cannabinoids product line. The Company would combine its two Patent pending technologies, the MMJ Patent, a patent for delivering medical marijuana / cannabis to the body by applying the medication onto the skin in an ointment base topical solution and the second Provisional patent for enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses. The Company would combine its proprietary solutions with CBD's and other natural products that treat psoriasis, fibromyalgia for pain and other ailments. The Company plans to continue to expand its (IP) "Intellectual Property Portfolio" in 2018.

What is CBD

CBD is a compound found in the Cannabis family of plants such as hemp. CBD is combined into our topical body care products like Elixr's Topical Balm, Serum, and  Spray.

CBD in Skin Care

CBD is an antioxidant. Antioxidants protect our skin from damaging exposure to smoke, UV rays,  and environmental pollutants. Cannabinoid receptors are located all throughout the skin, Topical CBD products interact with those receptors resulting homeostasis and healing. Studies show that CBD can help treat an array of skin conditions such as eczema, psoriasis, rosacea, and acne.

Dual Carrier Technology

Developed by a British Doctor and an American Pharmaceutical Company. Our Topical Products are formulated using Viaderma Pharmaceutical's Patent Pending Dual Carrier Technology. CBD is formulated into the carrier solution. This solution is then mixed with the professionally crafted skin care product using critically Essential Oils to maximize skin health care regime.


Elixr Hemp CBD Product Line


Our Elixr Hemp CBD Product line has a CBD Absorption Rate of 92% powered by Viaderma Pharmaceutical’s Patent Pending Dual Carrier Technology. Elixr Cannabis has the exclusive global rights to this groundbreaking technology combined with any Cannabinoids. Our products are second to none due to this independent laboratory tested high absorption rate combined with Elixr’s CDB profile.

Our CBD and Terpene profile, enriched with specific Essential Oils, Vitamin C, and Vitamin D, is crafted to alleviate Chronic Dry Skin, Psoriasis, Eczema, Rosacea, and many other skin conditions. CBD is known to have Anti-Inflammatory, Anti-Oxidant, and Anti-Aging properties that absorbs into the skin and provides overall healing benefits.

All our products are proudly Cruelty-free, 100% Toxin-free, Sodium Lauryl Sulfate free, Phthalate free, Parabens free, Petrochemicals free, Triclosan-free, Diethanolamine free and best of all, are handcrafted in Victoria, BC.


"What is Intellectual Property?"
- A Publication by the World Intellectual Property Organization -

2014 Provisional TBD TBD Is this referenced patent application an expired mmj provisional app from 2014? Otiko hasn't explained what happened here. BIOGENX 87290961 641 - Non-Final Action
2016  Patent App TBD TBD "its proprietary innovative transdermal delivery system" VITASTEM 87227123 681 - Publication/Issue Review Complete
2017 "Cannabis Provisional Patent"
(Incorrect Term)
62466209  Was this filed to replace the expired provisional cannabis app from 2014?      
2017 "enhanced antibiotic and drug delivery for "Aqueous Topical Applications" for human and veterinarian uses" 62433964 Is this related to the Viabecline product developed by the Phillips Company using their patent?      
Business Name Owner Registered Otiko's Role
19772 Trident Lane
Huntington Beach, CA 92646
Garrett Adams NV
First registered 12.14.16
Co-owns BIOGENX Trademark - Percent of BIOGENX business owned is unknown
NOTE: The news of BIOGENX as distributor did not reveal Otiko's ownership role.
Chemo-Pharma, Ltd  TBD No result from search
in Canada, England & India
Coast to Coast Podiatry, Inc.
6648 Reseda Blvd
Reseda, CA 91335
 First Registered 06.14.11
Updated 07.13.16
 Otiko states he is "Minority Owner" in his 12.09.16 Video Interview.
He is the named CEO, CFO, Secretary.  He was also sole director until filing of July 2016.
Sole Director is now his wife, Ekaterina Otiko.  Is Ekaterina the majority owner?
NOTE: The news of Coast to Coast as a distributor did not disclose Otiko's ownership role.




Day Range:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
PlusOneCoin Top Posts Free PlusOneCoin
No plusone'd posts yet. Be the first!
Post Subject
EVERYBODY: Get back and stay ON-TOPIC here. The topic IH Geek [Dave] 03/05/2017 03:10:04 PM
Must be tough to keep cheering for the Daboombooms 08/12/2022 09:24:47 PM
Hopefully not. Next week will be our week. Budman33 08/12/2022 06:04:24 PM
Post that the DR is out of the Grandmasim 08/12/2022 05:00:04 PM
That group of affiliated wound care practices, which YM4208 08/12/2022 02:06:11 PM
CEO is insane and disrespectful... Where are the Fdc4 08/12/2022 01:56:23 PM
Agree. That’s $135K better than ZERO Beninvest 08/11/2022 09:47:21 PM
I surmise the 2nd quarterly will be just gameccks1 08/11/2022 09:34:42 PM
Thanks for this. These people are insane Daboombooms 08/11/2022 08:50:09 PM
Thank you for your opinion. Here’s an old PR- Beninvest 08/11/2022 08:03:32 PM
Come on. Send in the clowns. What do sunrise73 08/11/2022 07:44:10 PM
Quarterly due next week I believe. I am Beninvest 08/10/2022 09:33:10 PM
WOW! Crickets. Out of excuses and nonsense it sunrise73 08/10/2022 07:23:40 PM
Dr. OTIKO = STEPHEN BROWN FROM HPIL.... Same Fdc4 08/10/2022 02:03:14 AM
I CALLED IT.ARREST OTIKO. ORCA 08/08/2022 09:45:45 PM
Dr Otiko is a failure. History tells me Daboombooms 08/08/2022 09:26:51 PM
This CEO Dr. O, not sure what is Fdc4 08/08/2022 06:18:27 PM
What’s new….. I don’t expect a PR until Here Today 08/08/2022 01:58:22 PM
The DOC is out of the country won’t NeverShort 08/08/2022 01:57:29 PM
I sent an email over the weekend. Awaiting Beninvest 08/08/2022 12:53:44 PM
"NO BIG DEAL" ????? Huh??? Grandmasim 08/08/2022 12:37:18 PM
Perhaps us investors try to reach the Dr. retired early 08/08/2022 12:12:38 PM
So we wait till next week big F******* deal slops 08/08/2022 11:31:02 AM
Tons of great posts. Here is one from sunrise73 08/08/2022 06:03:21 AM
A lot of great posts! $VDRM share price, Hummingbird2 08/06/2022 08:21:26 PM
Why choose Vitastem Wound Care Treatment Vitastem is an FDA tw0122 08/06/2022 06:45:12 PM
Good stuff - thanks for sharing Beninvest 08/06/2022 06:38:26 PM
I have used it with great results, thanks Budman33 08/06/2022 06:00:01 PM
Check-out these Vitastem web sites: indyterp 08/06/2022 05:57:40 PM
And the fabulous testing results should be announced. indyterp 08/06/2022 05:51:15 PM
Oh definitely! Daboombooms 08/06/2022 05:32:46 PM
I expect news this week, big orders, new Budman33 08/06/2022 04:09:16 PM
That’s a very conservative approach, based on the Fdc4 08/06/2022 03:55:22 PM
Should be .40+! indyterp 08/06/2022 10:19:13 AM
Within a 9 month window I believe we Budman33 08/06/2022 06:37:09 AM
Been a good week. Glad when so many Budman33 08/05/2022 05:26:16 PM
Another GREEN DAY it's all good $$ slops 08/05/2022 04:54:34 PM
Thanks for reposting some of my factual posts slops 08/05/2022 04:52:26 PM
Nope my posts are ALL FACT$ Thank You slops 08/05/2022 03:26:21 PM
This is not a stock for the weak slops 08/05/2022 03:20:03 PM
Just a matter of days PLENTY TO SELL slops 08/05/2022 03:16:51 PM
What a foolish thing to post JUST WATCH slops 08/05/2022 03:15:48 PM
Are you saying they will never have product again? Beninvest 08/05/2022 02:35:36 PM
What would a salesperson sell? Have you seen sunrise73 08/05/2022 01:55:54 PM
*ANY* revenue is a good thing** Beninvest 08/05/2022 01:22:18 PM
Agree. And revenue is good IMO. Plenty of Beninvest 08/05/2022 01:21:38 PM
The most logical outcome for the 2nd Qtr gameccks1 08/05/2022 12:51:15 PM
Quarterly due soon. Maybe they’ll pair that with Beninvest 08/05/2022 10:33:23 AM
Post Subject